Posts

Cellmid alopecia patent granted in Europe for évolis hair therapy

Cellmid alopecia patent granted in Europe for évolis hair therapy

/in /by

Cellmid alopecia patent granted in Europe for évolis hair therapy

Notification of the intention to grant a patent will increase the commercial value of the évolis® brand beyond sales.

The évolis® products have been developed by wholly-owned subsidiary, Advangen Limited

Cellmid Limited (ASX:CDY) has been advised of the European Patent Office’s intention to grant a patent to protect technologies included in the évolis® hair therapy formulations.

This patent titled ‘Method of treatment of Alopecia with Monoterpenoids’ provides protection in key European territories for hair therapy formulations comprising monoterpenoids.

This class of small molecules is originally derived from botanical extracts.

Cellmid CEO Maria Halasz said: “The upcoming granting of this patent represents a key milestone for the company’s évolis® products and adds further commercial value to the brand beyond the current sales.”

Imminent granting of this patent comes at a key time in the expansion of the company’s distribution in line with its growth strategy.

It is expected to strengthen ongoing negotiations with potential retail and distribution partners in Europe and other jurisdictions.

The method covered by the patent involves administering a topical formulation containing a monoterpenoid to inhibit the hair growth cycle regulatory protein fibroblast growth factor 5 (FGF5).
Inhibitors of FGF5

Detailed scientific studies have shown that FGF5 activity in hair follicles is associated with disruption of the hair cycle, leading to withdrawal from the growth or anagen phase and entry into the regressive catagen phase, followed by follicle rest and hair loss.

Rigorous testing of various monoterpenoid compounds by the Advangen Hair Gene Research Laboratory in Japan showed that several were potent inhibitors of FGF5, enabling hair follicles to maintain growth in the anagen phase.

Halasz said granting of this patent in Europe was an important step for this patent family and was a promising sign for successful grant in other countries such as US, Japan and China.

In these countries where significant additional markets for the company’s hair care products exist, the same patent is under examination.
Reduction of hair loss

Topical application of formulations containing key botanical extracts and FGF5-inhibiting monoterpenoids is central to Advangen’s évolis® products against hair loss.

The évolis® products containing monoterpenoid compounds have been shown to reduce hair loss and increase the number of actively growing follicles in a blinded, placebo-controlled clinical study.

These results were published in the journal Clinical, Cosmetic, and Investigational Dermatology (2017) 10: 71-85.

The monoterpenoids-alopecia patents are held by Cellmid’s wholly-owned subsidiary, Advangen Limited.

Cellmid alopecia patent granted in Europe for évolis hair therapy

Source

 

Previous Posts

Cellmid alopecia patent granted in Europe for évolis hair therapy

Cellmid alopecia patent granted in Europe for évolis hair therapy

/in /by

Cellmid alopecia patent granted in Europe for évolis hair therapy

Notification of the intention to grant a patent will increase the commercial value of the évolis® brand beyond sales.

The évolis® products have been developed by wholly-owned subsidiary, Advangen Limited

Cellmid Limited (ASX:CDY) has been advised of the European Patent Office’s intention to grant a patent to protect technologies included in the évolis® hair therapy formulations.

This patent titled ‘Method of treatment of Alopecia with Monoterpenoids’ provides protection in key European territories for hair therapy formulations comprising monoterpenoids.

This class of small molecules is originally derived from botanical extracts.

Cellmid CEO Maria Halasz said: “The upcoming granting of this patent represents a key milestone for the company’s évolis® products and adds further commercial value to the brand beyond the current sales.”

Imminent granting of this patent comes at a key time in the expansion of the company’s distribution in line with its growth strategy.

It is expected to strengthen ongoing negotiations with potential retail and distribution partners in Europe and other jurisdictions.

The method covered by the patent involves administering a topical formulation containing a monoterpenoid to inhibit the hair growth cycle regulatory protein fibroblast growth factor 5 (FGF5).
Inhibitors of FGF5

Detailed scientific studies have shown that FGF5 activity in hair follicles is associated with disruption of the hair cycle, leading to withdrawal from the growth or anagen phase and entry into the regressive catagen phase, followed by follicle rest and hair loss.

Rigorous testing of various monoterpenoid compounds by the Advangen Hair Gene Research Laboratory in Japan showed that several were potent inhibitors of FGF5, enabling hair follicles to maintain growth in the anagen phase.

Halasz said granting of this patent in Europe was an important step for this patent family and was a promising sign for successful grant in other countries such as US, Japan and China.

In these countries where significant additional markets for the company’s hair care products exist, the same patent is under examination.
Reduction of hair loss

Topical application of formulations containing key botanical extracts and FGF5-inhibiting monoterpenoids is central to Advangen’s évolis® products against hair loss.

The évolis® products containing monoterpenoid compounds have been shown to reduce hair loss and increase the number of actively growing follicles in a blinded, placebo-controlled clinical study.

These results were published in the journal Clinical, Cosmetic, and Investigational Dermatology (2017) 10: 71-85.

The monoterpenoids-alopecia patents are held by Cellmid’s wholly-owned subsidiary, Advangen Limited.

Cellmid alopecia patent granted in Europe for évolis hair therapy

Source

 

Previous Posts

Cellmid anti-ageing hair loss treatment

Cellmid anti ageing hair loss treatment

/in /by

Cellmid just got its anti ageing, hair loss treatment into two major US stores Health

Biotech Cellmid is going global with its anti ageing hair product Evolis, securing distribution through major US department stores and preparing for a launch in Japan.

The Evolis products are designed to stop FG45, a biological signal that halts the hair production cycle and triggers hair to stop growing.

On Wednesday Cellmid told investors the Evolis range would be permanently stocked in Neiman Marcus and Bloomingdale’s from 2018, after successful online sales trials with the two US retailers.

The stock was up 6 six percent at 46c by 11.30am. It’s traded between 35c and 58c over the past year.

“Our specially trained sales staff – hair biologists – do a hair follicle test with a microscope connected to a tablet,” chief executive Maria Halasz told Stockhead.

evolis hair loss

“Customers can see their own hair follicles and are able to recommend a personalised set of products for each customer.

“Our average conversion rate is very high — over 50 percent — and we can do an assessment within 5-10 minutes per customer,” she said.

“We are targeting the 2,500 or so premium retailers in the US in the first instance and expect around 10% of this market in the next 12-18 months,” Ms Halasz said.

The company says even if it just secures distribution through 25 US stores, this could result in more sales revenue than the entire Australian market for its products.

Cellmid also confirmed this morning it would be selling the Evolis Professional range into Japan through speciality retailers and hair salons in the country from July.

Besides its Evolis hair loss treatment, Cellmid is also working on drug treatments for use on solid tumors, as well as licensing a non-injectable dermal cosmetic filler, Fillerina, which is planned for an Australian launch soon.

In the March quarter, Cellmid made $2.2 million from customers and burned $704,000. It had $3.4 million in the bank at March 31.

Cellmid anti ageing hair loss treatment

Source

Cellmid makes move to sell hair loss products into China